Prolaris is a prostate-specific antigen (PSA) genetic test that analyzes cancer cells of patients diagnosed with prostate cancer. The test determines the aggressiveness of the cancer, helping physicians identify low- and medium-risk patients.

This testing enables doctors to actively monitor a patient’s cancer and choose less aggressive forms of treatment for less advanced cases, ultimately helping some patients avoid unnecessary surgery or radiation.